Smooth Muscle Cell Mineralocorticoid Receptor Deletion Leaves Early Plaque Biology Unchanged
A new mouse study leaves a specific vascular question unanswered in a very direct way: eliminating the smooth muscle cell mineralocorticoid receptor did not change early atherosclerosis in either male or female ApoE-knockout mice. The work matters because mineralocorticoid signaling has already been tied to arterial inflammation, plaque burden, and sex-specific differences in vascular disease, yet the smooth muscle compartment had not been tested in females before this experiment.
The investigators built on a broader pattern in cardiovascular biology. Men and women do not develop plaque in identical ways, and human pathology has repeatedly shown that male plaques tend to be more inflamed while female plaques contain more smooth muscle cells and extracellular matrix. Aldosterone biology sits upstream of that process. When aldosterone activates the mineralocorticoid receptor, it can alter gene transcription across several vascular cell types, including endothelial cells, leukocytes, and smooth muscle cells. Because obesity is associated with higher aldosterone and higher myocardial infarction risk, the pathway has remained attractive as a target for atherosclerosis research.
No Signal From the Smooth Muscle Compartment in Either Sex
Male and female mice carrying ApoE deficiency were crossed with MRflox/flox × SMA-Cre-ERT2 animals to generate smooth muscle cell-specific receptor knockout and intact littermate controls. Tamoxifen was given to activate Cre recombinase, and all animals then received an 8-week high-fat diet. The design allowed a direct comparison of male and female littermates under the same atherogenic pressure.
MR knockdown was confirmed in whole aortas from both sexes. After that genetic confirmation, the phenotype remained stubbornly unchanged.
Aldosterone levels did not differ by sex and did not change with smooth muscle cell MR deletion. Neither fasting glucose, cholesterol, blood pressure, nor body weight was altered by the knockout, although males weighed more than females overall. In other words, the receptor deletion was real, but the usual metabolic and hemodynamic readouts stayed flat.
Plaque Size, Lipid Content, Fibrosis, and Inflammatory Markers Stayed Stable
Aortic root histology offered the clearest answer. Smooth muscle cell MR deletion did not significantly affect plaque area in male or female mice, even though female animals had larger plaques than males overall. The histologic profile was similarly resistant to change across both genotypes.
Oil-Red-O staining showed no significant sex or genotype difference in the proportion of plaque made up of necrotic core or neutral lipid. Masson’s Trichrome staining found no effect on fibrosis. Immunofluorescence for smooth muscle actin and Mac2 also showed no meaningful shift with knockout, and neither marker differed significantly by sex.
This is an important negative result. The smooth muscle receptor was removed, yet the expected downstream remodeling signals never emerged in early lesion development. For a pathway long suspected of influencing vascular inflammation and plaque architecture, the absence of effect in this model narrows the likely cell types responsible for the protective effects seen with broader mineralocorticoid receptor blockade.
Why the Smooth Muscle Cell Result Differs From Other Mineralocorticoid Receptor Studies
The biological logic behind the null finding is not hard to imagine. Smooth muscle cells do contribute to plaque growth, fibrosis, calcification, and the structural composition that can make a lesion more or less rupture-prone. If aldosterone signaling were acting primarily through that compartment, one would expect changes in plaque size, matrix content, or smooth muscle representation inside the lesion. None appeared here.
By contrast, prior work in the same broader research program has pointed to endothelial and myeloid mineralocorticoid receptor signaling as more relevant to plaque inflammation, at least in male mice. That makes the present study a useful boundary marker. It suggests that in this early ApoE-knockout model, smooth muscle cell MR is not the dominant driver of plaque initiation or early remodeling under high-fat feeding.
The sex comparison adds another layer. Female mice did not show a distinct smooth muscle receptor effect despite the recognized sex differences in human plaque biology and in prior mouse studies of other vascular cell types. Female plaques were larger overall, but the knockout did not shift their composition. The result argues against a simple model in which smooth muscle mineralocorticoid signaling explains the female vascular phenotype at this stage of disease.
Early Atherosclerosis May Be Too Soon for This Pathway to Matter
Timing likely shaped the outcome. These animals were studied after 8 weeks of high-fat diet, a period that produces aortic root plaque but still reflects relatively early atherosclerosis in this model. The lesions were large enough to quantify but perhaps not advanced enough for smooth muscle receptor signaling to drive a measurable phenotype. In advanced human plaques, smooth muscle cell behavior may become more prominent as fibrous cap formation, extracellular matrix deposition, and plaque stabilization evolve over time.
That possibility does not rescue the pathway here, but it does explain why a negative study can still be informative. If a receptor deletion fails to alter plaque burden, lipid accumulation, fibrosis, or inflammatory cell presence during early disease, then any future benefit from smooth muscle targeting would likely need to appear later, under different metabolic conditions, or in a different lesion context.
What This Means for Mineralocorticoid Receptor Targeting
For now, the study points away from smooth muscle cells as the key mineralocorticoid-responsive compartment in this model of early atherosclerosis. The broader aldosterone-mineralocorticoid axis still looks relevant to cardiovascular disease, especially in obesity and in pathways that affect blood pressure and vascular inflammation. But the cellular target appears to matter.
In practical terms, this narrows the field. If mineralocorticoid receptor antagonism reduces atherosclerosis in some settings, the benefit is unlikely to be explained by smooth muscle cell signaling alone. Endothelial and myeloid mechanisms remain more plausible candidates, and the female vascular response still needs additional dissection in later-stage disease and other models.
The study also has a disciplined design feature that strengthens the interpretation: both sexes were examined directly, the genetic knockout was confirmed, and the histology was blinded. Even so, the experimental window was limited to early plaque biology under a single dietary and genetic context. Whether smooth muscle cell MR becomes relevant in more advanced lesions, in longer feeding paradigms, or under different hormonal conditions remains unresolved by this dataset.